Indomethacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Indomethacin: Brachydactyly-syndactyly syndrome
One-Sentence Summary
Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) used for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout and related musculoskeletal conditions. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, a rare genetic skeletal disorder. There are no clinical trials and no publications supporting this prediction, so it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Indomethacin is generally understood to be a non-selective COX-1/COX-2 inhibitor. It reduces prostaglandin-mediated inflammation, pain and fever, and this underpins its use in inflammatory joint disease.
Brachydactyly-syndactyly syndromes are developmental skeletal disorders with a genetic basis. COX inhibition has no established role in their pathophysiology, and an anti-inflammatory drug is not expected to correct a structural genetic defect. The high score (rank 350 in the model’s overall ranking) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It does not reflect a pharmacological rationale.
No mechanistic link has been identified for this prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 2454E | Arthrexin | Capsule 25 mg (oral) | Not specified in the data compiled |
Safety Considerations
Warning and contraindication text from the product label was not available. Please refer to the TGA-approved Product Information (PI) for authoritative safety information.
Contraindication-related conditions (knowledge graph, not label text): The knowledge graph links indomethacin with the following conditions. These should be verified against the PI.
- Cardiovascular: hypertension, myocardial infarction and coronary thrombosis, heart and cardiovascular disease, intracerebral haemorrhage
- Gastrointestinal: gastric, duodenal and active peptic ulcer disease, ulcerative colitis and inflammatory bowel disease, necrotising enterocolitis, oesophageal dyskinesia
- Renal and hepatic: kidney disease, liver disease, gallbladder disease
- Haematological: thrombocytopenia, blood coagulation disease, haemoglobinopathy
- Respiratory: asthma (intrinsic and allergic)
- Neuropsychiatric: epilepsy, anxiety, neurotic and dysthymic disorders
- Other: infectious disease, pyoureter
Drug interactions: The data list 252 recorded interactions. The entries reviewed (from DDInter) include:
- Moderate: corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), acetylsalicylic acid, metformin, sulfonylureas (glimepiride, chlorpropamide), mesalazine, balsalazide, aprepitant, potassium salts (citrate, bicarbonate), and bowel preparations (picosulfuric acid, polyethylene glycol with electrolytes)
- Minor: H2 blockers (famotidine, ranitidine, cimetidine) and linaclotide
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone, with no trials, no literature and no plausible mechanism for a genetic skeletal malformation. It does not justify further investment at this stage.
Among the other predictions, juvenile idiopathic arthritis (rank 8, evidence level L3) has a plausible mechanism and a dated double-blind comparison of ketoprofen and indomethacin in juvenile chronic arthritis (1978). It is also largely established practice, so its value as a new indication is limited. It may merit separate assessment if a repurposing question is pursued.
To proceed, the following is needed:
- Mechanism of action data to test whether any biological link exists to this condition
- Product Information (warnings, contraindications and approved indications) for ARTG 2454E, which is currently a blocking gap for safety screening
- Any preclinical or clinical evidence linking indomethacin to brachydactyly-syndactyly syndrome; without it, this candidate should not advance
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.